Antiretroviral treatment regimen outcomes among HIV-infected prisoners

HIV Clinical Trials

Volumn 8, Issue 4, 2007, Pages 205-212

  Springer, Sandra A ^a   Friedland, Gerald H ^a   Doras, Gheorghe ^a   Pesanti, Edward ^b   Altice, Frederick L ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Antiretroviral therapy; CD4 lymphocyte count; HAART; HIV 1 RNA; HIV AIDS; Incarceration; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Prisoners; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRISONER; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONNECTICUT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PRISONERS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34548282967     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0804-205     Document Type: Article

References (34)

1. National Commission on Correctional Health Care. The Health Status of Soon-to-be-Released Inmates: A Report to Congress March, 2002. Available at: http://www.ncchc.org/pubs/pubs_stbr.html Accessed March 27, 2006.
2. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305-312.
3. Maruschak L. HIV in Prisons, 2000 [Bureau of Justice Statistics bulletin]. Washington, DC: Department of Justice; October 2002. Available at: http://www.ojp.gov/bjs/pub/pdf/hivp00.pdf Accessed March 27, 2006.
4. Palella FJ, Delaney K, Moorman A, HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.
5. Centers for Disease Control (CDC). Decrease in AIDS-related mortality in a state correctional system-New York, 1995-1998. MMWR Morb Mortal Wkly Rep. 1999;47(51-52):1115-1117.
6. Pollack H, Khoshnood K, Altice FL. Health care delivery strategies for criminal offenders. J Health Care Finance. 1999;26(1):63-77.
7. Restum ZG. Public health implications of substandard correctional health care. Am J Public Health. 2005;95(10):1689-1691.
8. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754-1760.
9. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296(7):769-781.
10. Riddler S, Haubrich R, DiRienzo G, et al, AIDS Clinical Trials Group 5142 Study Team. A prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
11. Connecticut Department of Correction. July 1, 2003 Statistics. Available at: http://www.doc.state.ct.us/report/stat20030701.htm
12. Altice FL, Mostashari F, Selwyn PA, et al. Predictors of HIV infection among newly sentenced male prisoners. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(5):444-453.
13. Altice FL, Khoshnood K, Blankenship KM, et al. Determinants of HIV seroprevalence and seroincidence of new entrants to a women's prison. Paper presented at: XI International Conference on AIDS; 1996; Vancouver, Canada.
14. US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on Clinical Practices for Treatment of HIV infection convened by the Department of Health and Human Services; October, 2006. Available at: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf Accessed November 10, 2006.
15. Smeaton L, DeGruttola V, Robbins G, Shafer R, ACTG 384 (AIDS Clinical Trials Group). A strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials. 2001;22(2):142-159.
16. Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17(9):1339-1349.
17. Hammer S, Vaida F, Bennett K, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288(2):169-180.
18. Gulick R, Hu X, Fiscus S, et al. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002;186(5):626-633.
19. Palella FJ, Chmiel J, Moorman A, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16(12):1617-1626.
20. Phillips A, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15(18):2379-2384.
21. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Ann Intern Med. 2000;160(8):1123-1132.
22. Celantano D, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544-546.
23. Ostrop N, Hallett K, Gill M. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34(6):703-709.
24. Miller LG, Golin CE, Hays R, et al. Impact of antiretroviral regimen switches on adherence. HIV Clin Trials. 2002;3(5):355-360.
25. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656-661.
26. Bartlett J, Fath M, DeMasi R, et al. An updated meta-analysis of triple combination therapy in antiretroviral-naïve HIV-infected adults. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections (CROI); February 22-25, 2005; Boston.
27. Altice FL, Springer S. Reply to Babudieri et al. Clin Infect Dis. 2005;40:322-323.
28. Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476-1481.
29. Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart R Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84-88.
30. Celentano D, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544-546.
31. Strathdee S, Palepu A, Cornelisse P, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547-549.
32. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767-774.
33. Altice FL, Mostashari F, Friedland G. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;28(1):47-58.
34. Flanigan T, Rich J, Spaulding A. HIV care among incarcerated persons: a missed opportunity. AIDS. 1999;13:2475-2476.